
Citius Pharmaceuticals CTXR
€ 0.70
-2.52%
Quartalsbericht 2025-Q4
hinzugefügt 13.02.2026
Citius Pharmaceuticals ROCE 2011-2026 | CTXR
ROCE Jährlich Citius Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -59.93 | -40.44 | -32.4 | -17.8 | -44.64 | -63.98 | -49.48 | -45.5 | -44.43 | 508.48 | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 508.48 | -63.98 | 10.99 |
ROCE Vierteljährlich Citius Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -56.86 | -46.64 | -58.96 | -57.78 | -52.93 | -36.99 | -8859.06 | -17668.81 | -17666.73 | -8840.89 | -8865.95 | -51.95 | -46.74 | -47.0 | -35.8 | -32.08 | -28.99 | -53.17 | -79.6 | -89.17 | -118.18 | -105.78 | -109.46 | -117.26 | -106.74 | -101.9 | -99.81 | -86.43 | -80.62 | -78.79 | -71.46 | -73.39 | -69.91 | -75.74 | -53.87 | -56.27 | -60.34 | 48.98 | 405.01 | 539.5 | 752.05 | 780.5 | 498.65 | 377.02 | 299.53 | 210.01 | 227.09 | 250.3 | 133.82 | 116.65 | 58.29 | 48.38 | 47.75 | 47.92 | 112.33 | 128.61 | 135.58 | 97.29 | 29.76 | 8.32 |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 780.5 | -17668.81 | -979.81 |
ROCE anderer Aktien in der Pharmaeinzelhändler
| Name | ROCE | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.85 | 3.22 % | $ 9.26 B | ||
|
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 330.55 | -0.85 % | $ 43.3 B | ||
|
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | ||
|
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
-164.32 | $ 7.51 | 1.21 % | $ 74.2 M | ||
|
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.68 | - | $ 1.01 B | ||
|
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
-4.81 | $ 99.49 | 0.02 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - | ||
|
Burford Capital Limited
BUR
|
14.24 | $ 4.79 | 1.06 % | $ 771 M | ||
|
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | ||
|
Cabaletta Bio
CABA
|
-153.72 | $ 3.46 | 1.62 % | $ 348 M | ||
|
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.17 | -2.16 % | $ 5.22 M | ||
|
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
72.06 | $ 1.5 | -3.23 % | $ 386 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
211.07 | $ 4.24 | -0.12 % | $ 453 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.54 | -0.18 % | $ 3.12 B | ||
|
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.48 | -1.01 % | $ 394 M | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-75.78 | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
156.13 | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
-54.51 | $ 33.97 | 0.3 % | $ 2.26 B | ||
|
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
-353.49 | $ 2.67 | -2.91 % | $ 1.18 M | ||
|
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B |